Analysis of the efficacy and possible side effects of ruxolitinib cream (Opzelura)

Ruxolitinib cream (Opzelura) is a topical JAK inhibitor. Its main mechanism of action is to inhibit the excessive activation of inflammatory factors by blocking the JAK-STAT signaling pathway, thereby regulating the immune response. The drug is mainly used clinically to treat mild to moderate atopic dermatitis and vitiligo. It can relieve skin itching, inflammation and erythema, promote melanin production in patients with vitiligo, and help the skin pigment gradually recover.

For patients with atopic dermatitis, ruxolitinib cream can effectively relieve local inflammatory reactions and reduce symptoms of dry skin, itching and erythema. Compared with traditional glucocorticoids or calcineurin inhibitors, ruxolitinib cream has a lower risk of skin atrophy when used long-term and is considered a relatively safe alternative. Most patients can see significant improvement in skin inflammation and improved quality of life after several weeks of continuous use.

In the treatment of vitiligo, ruxolitinib cream can promote the activation and migration of melanocytes, thereby helping the skin gradually restore pigment. Studies have shown that some patients can observe pigment reflux in white spots after continuous use for about 24 weeks, especially on the face and neck. However, the responses of different patients vary greatly, and the efficacy is closely related to the duration of the disease, the location of the lesions, and the individual immune status.

Ruxolitinib cream is a topical drug with limited systemic absorption, but local and mild systemic side effects may still occur. Common local adverse reactions include Mild stinging, itching, erythema, or acne-like skin changes. A small number of patients may develop upper respiratory tract infection or headache. Because it is an immune pathway inhibitor, long-term or large-area use may theoretically increase infection or immune-related risks. Therefore, it needs to be used under the guidance of a doctor and avoid excessive long-term application in large doses.

Reference materials:https://www.drugs.com/